Research output per year
Research output per year
Fingerprint
Dive into the research topics where Patrick Forde is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis
Liang, K. L., Tackett, S., Myers, S., Brahmer, J. R., Browner, I. S., Ettinger, D. S., Forde, P. M., Hales, R. K., Hann, C. L., Lam, V., Marrone, K. A., Patel, T., Peterson, V., Sagorsky, S., Turner, M., Voong, K. R., Naidoo, J. & Feliciano, J. L., Jun 2022, In: Current Oncology. 29, 6, p. 4342-4353 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
Rosner, S. & Forde, P. M., Apr 2022, In: Journal of Thoracic Oncology. 17, 4, p. 503-509 7 p.Research output: Contribution to journal › Editorial › peer-review
Open Access -
Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))
Friedlaender, A., Naidoo, J., Luigi Banna, G., Metro, G., Forde, P. & Addeo, A., Mar 2022, In: Cancer Treatment Reviews. 104, 102358.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., & 9 others, Dec 2022, In: npj Precision Oncology. 6, 1, 13.Research output: Contribution to journal › Article › peer-review
Open Access -
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
Gridelli, C., Peters, S., Mok, T., Forde, P. M., Reck, M., Attili, I. & de Marinis, F., Feb 2022, In: ESMO Open. 7, 1, 100355.Research output: Contribution to journal › Review article › peer-review
Open Access